KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Astrazeneca (AZN) over the last 15 years, with Q4 2025 value amounting to -$1.4 billion.

  • Astrazeneca's Cash from Investing Activities fell 2243.86% to -$1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.8 billion, marking a year-over-year increase of 1468.67%. This contributed to the annual value of -$6.8 billion for FY2025, which is 1468.67% up from last year.
  • Per Astrazeneca's latest filing, its Cash from Investing Activities stood at -$1.4 billion for Q4 2025, which was down 2243.86% from -$2.0 billion recorded in Q3 2025.
  • Astrazeneca's Cash from Investing Activities' 5-year high stood at $555.0 million during Q1 2021, with a 5-year trough of -$10.5 billion in Q3 2021.
  • In the last 5 years, Astrazeneca's Cash from Investing Activities had a median value of -$1.2 billion in 2023 and averaged -$1.8 billion.
  • Per our database at Business Quant, Astrazeneca's Cash from Investing Activities surged by 606666.67% in 2021 and then tumbled by 64166.67% in 2023.
  • Astrazeneca's Cash from Investing Activities (Quarter) stood at -$913.0 million in 2021, then rose by 12.38% to -$800.0 million in 2022, then surged by 35.0% to -$520.0 million in 2023, then plummeted by 127.12% to -$1.2 billion in 2024, then fell by 22.44% to -$1.4 billion in 2025.
  • Its Cash from Investing Activities stands at -$1.4 billion for Q4 2025, versus -$2.0 billion for Q3 2025 and -$2.1 billion for Q2 2025.